The Coalition for Accelerating Standards and Therapies (CFAST)
CFAST is an initiative formed to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health. CFAST was initiated as a partnership between CDISC and the Critical Path Institute (C-Path). Since launching CFAST, CDISC and C-Path have worked to expand the TA Program Steering Committee (TAPSC) to ensure input from US FDA, the National Cancer Institute Enterprise Vocabulary Services (NCI EVS) and TransCelerate BioPharma (for more information on CFAST Governance, please see below). CDISC also initiated the CFAST Scientific Advisory Committee (SAC), which brings advice from the TAPSC organizations and also Innovative Medicines Initiative (IMI) and the Association of Clinical Research Organizations (ACRO).
The CFAST program is governed by the Therapeutic Area Standards Program Steering Committee (TAPSC). For more information about CFAST governance see the CFAST Committee Charter (link below). The steering committee meets every two weeks. Highlights and decisions of CFAST Steering Committee Meetings are updated regularly to summarize meetings from the previous quarter.
The Scientific Advisory Committee meets monthly. This committee provides scientific guidance for the CFAST enterprise programs, and scientific advice, as deemed appropriate, to CFAST Program Steering Committee(s) and other CFAST project-related teams as needed.
CFAST Participating Organizations
- Critical Path Institute
- Association of Clinical Research Organizations
- Innovative Medicines Initiative
- National Cancer Institute - Enterprise Vocabulary Services
- TransCelerate BioPharma Inc.
- U.S. Food and Drug Administration